title: The case for combined chemotherapy-peptide receptor radionuclide therapy (chemo-PRRT) strategy in metastatic neuroendocrine tumor: predicting and looking at the possible case scenarios.
authors.affiliation: Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Jerbai Wadia Road Parel, Mumbai, 400 012, India. drsanb@yahoo.com.
authors.forename: Sandip
authors.initials: S
authors.lastname: Basu
authors.affiliation: Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
authors.forename: Vikas
authors.initials: V
authors.lastname: Ostwal
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy / Q000379:methods; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy / Q000379:methods; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging / Q000556:secondary* / Q000628:therapy*; D011868:Radioisotopes / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011868:Radioisotopes
keywords: 177Lu-DOTATATE; 68Ga-DOTATATE; Chemotherapy; FDG-PET/CT; Neuroendocrine tumor; Peptide receptor radionuclide therapy